Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review.

× No keyword cloud information.

17 in total

1. Neuroprotective effects of neuroactive steroids in the spinal cord and peripheral nerves.

Authors: Roberto C Melcangi; Ayikoe G Mensah-Nyagan
Journal: J Mol Neurosci Date: 2006 Impact factor: 3.444

2. Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.

Authors: Jacob Kach; Tiha M Long; Phillip Selman; Eva Y Tonsing-Carter; Maria A Bacalao; Ricardo R Lastra; Larischa de Wet; Shane Comiskey; Marc Gillard; Calvin VanOpstall; Diana C West; Wen-Ching Chan; Donald Vander Griend; Suzanne D Conzen; Russell Z Szmulewitz
Journal: Mol Cancer Ther Date: 2017-04-20 Impact factor: 6.261

3. Mifepristone inhibits GRβ coupled prostate cancer cell proliferation.

Authors: Martin Ligr; Yirong Li; Susan K Logan; Samir Taneja; Jonathan Melamed; Hebert Lepor; Michael J Garabedian; Peng Lee
Journal: J Urol Date: 2012-07-21 Impact factor: 7.450

4. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.

Authors: Russell Z Szmulewitz; Elizabeth Chung; Hikmat Al-Ahmadie; Silver Daniel; Masha Kocherginsky; Aria Razmaria; Gregory P Zagaja; Charles B Brendler; Walter M Stadler; Suzanne D Conzen
Journal: Prostate Date: 2011-05-11 Impact factor: 4.104

5. Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.

Authors: Yoshitsugu Mitani; Sue-Hwa Lin; Kristen B Pytynia; Renata Ferrarotto; Adel K El-Naggar
Journal: Clin Cancer Res Date: 2019-11-26 Impact factor: 12.531

6. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.

Authors: Masis Isikbay; Kristen Otto; Steven Kregel; Jacob Kach; Yi Cai; Donald J Vander Griend; Suzanne D Conzen; Russell Z Szmulewitz
Journal: Horm Cancer Date: 2014-03-11 Impact factor: 3.869

7. Targeting the glucocorticoid receptor in breast and prostate cancers.

Authors: Jacob Kach; Suzanne D Conzen; Russell Z Szmulewitz
Journal: Sci Transl Med Date: 2015-09-16 Impact factor: 17.956

8. Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice.

Authors: Claudia Raja Gabaglia; Alexandra DeLaney; Jennifer Gee; Ramesh Halder; Frank L Graham; Jack Gauldie; Eli E Sercarz; Todd A Braciak
Journal: J Transl Med Date: 2010-10-14 Impact factor: 5.531

9. Oral low-dose dexamethasone for androgen-independent prostate cancer patients.

Authors: Akira Komiya; Masaki Shimbo; Hiroyoshi Suzuki; Takashi Imamoto; Tomonori Kato; Satoshi Fukasawa; Naoto Kamiya; Yukio Naya; Ikuo Mori; Tomohiko Ichikawa
Journal: Oncol Lett Date: 2010-01-01 Impact factor: 2.967

Review 10. Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.

Authors: Sujata Narayanan; Sandy Srinivas; David Feldman
Journal: Nat Rev Urol Date: 2015-12-08 Impact factor: 14.432